Abstract

Dysphagia is common in inflammatory myopathies and usually responds to corticosteroids. Severe dysphagia requiring feeding by percutaneous endoscopic gastrostomy is associated with significant morbidity and high mortality. A 56-year old African Black woman initially presented with systemic sclerosis (SSC) - myositis overlap and interstitial lung disease. She responded to high dose corticosteroids and cyclophosphamide followed by azathioprine, with improvement in her lung function and regression of the skin changes. Six years later she had a myositis flare with severe dysphagia. Her myositis improved after high doses of corticosteroids, azathioprine and two doses of intravenous immunoglobulin (IVIG). As her dysphagia persisted, she was fed via a percutaneous endoscopic gastrostomy (PEG) tube and given a course of rituximab. Her dysphagia gradually resolved and the PEG tube was removed within two months. She received another dose of rituximab six months later and continued low dose prednisone and azathioprine. Her muscle power improved, weight returned to normal and she remained well 20 months after hospital discharge. Our patient with SSC-myositis overlap and severe dysphagia requiring PEG feeding, improved with high dose corticosteroids, azathioprine, two courses of IVIG and rituximab, and remained in remission 20 months after hospital discharge.

Highlights

  • Dysphagia is reported in up to 90% of patients with systemic sclerosis (SSC) and 20 - 84% of inflammatory myopathies, and may occur at any stage during the course of the disease[1]

  • We report about a patient with SSC - myositis overlap who was admitted with a myositis flare and severe dysphagia

  • Dysphagia is common in patients with inflammatory myopathies and its management includes rehabilitation measures, corticosteroids and other immunosuppressive agents, and rarely surgical measures such as cricopharyngeal myotomies and dilatations[9]

Read more

Summary

Introduction

Dysphagia is reported in up to 90% of patients with systemic sclerosis (SSC) and 20 - 84% of inflammatory myopathies, and may occur at any stage during the course of the disease[1]. Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report. Introduction Dysphagia is reported in up to 90% of patients with systemic sclerosis (SSC) and 20 - 84% of inflammatory myopathies, and may occur at any stage during the course of the disease[1]. Intravenous immunoglobulin (IVIG) and rituximab are effective in patients with severe, progressive or refractory inflammatory myopathy[4,5,6,7,8].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.